Jarad Martin, Senior Staff Specialist of Department of Radiation Oncology at Calvary Mater Hospital, shared on LinkedIn:
“A multidisciplinary discussion in collaboration with Astellas Pharma of how we might be able integrate the benefits of systemic therapy intensification for high risk biochemically recurrent prostate cancer using Enzalutamide informed by the EMBARK study with PSMAPET, metastasis directed therapy, and salvage radiotherapy.
Title: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer
Authors: Neal D. Shore, Murilo de Almeida Luz, Ugo De Giorgi, Martin Gleave, Geoffrey T. Gotto, Christopher M. Pieczonka, Gabriel P. Haas, Choung-Soo Kim, Miguel Ramirez-Backhaus, Antti Rannikko, Matko Kalac, Swetha Sridharan, Matt Rosales, Yiyun Tang, Ronald F. Tutrone Jr., Balaji Venugopal, Arnauld Villers, Henry H. Woo, Fong Wang, Stephen J. Freedland
Biochemically recurrent prostate cancer (BCR) is a rising prostate-specific antigen (PSA) level after initial curative treatment – such as surgery or radiation – without visible signs of cancer on standard imaging scans. It occurs in roughly 20% to 40% of men within 10 years of primary therapy.
Because PSA rises before tumors are large enough to appear on conventional CT or bone scans, BCR acts as an early warning signal that microscopic prostate cancer cells remain active in the body. Many men with BCR experience a very slow-moving course and live for well over a decade without symptoms, while a smaller high-risk subset requires prompt intervention to prevent metastasis.
You can also read:
- DASL-HiCaP Trial Shows Darolutamide Improves Metastasis-Free Survival in Very High-Risk Prostate Cancer
- CAPRI-3 Registry: PSMA PET/CT in Metastatic Castration-Sensitive Prostate Cancer
